Olivier Tshiani Mbaya
A5080300387- Viral Infections and Outbreaks Research
- Enhanced Recovery After Surgery
- Poxvirus research and outbreaks
- Cardiac, Anesthesia and Surgical Outcomes
- Hepatitis B Virus Studies
- Disaster Response and Management
- COVID-19 epidemiological studies
- Viral Infections and Vectors
- Bacillus and Francisella bacterial research
- Nutrition and Health in Aging
- Vaccine Coverage and Hesitancy
- SARS-CoV-2 and COVID-19 Research
- Herpesvirus Infections and Treatments
- Zoonotic diseases and public health
- Rabies epidemiology and control
- Health, Medicine and Society
- Bladder and Urothelial Cancer Treatments
- Colorectal Cancer Surgical Treatments
- Hepatitis Viruses Studies and Epidemiology
- Ethics in Clinical Research
- AI in cancer detection
- Cancer, Lipids, and Metabolism
- Metabolism, Diabetes, and Cancer
- Lipoproteins and Cardiovascular Health
- Telemedicine and Telehealth Implementation
National Institute of Biomedical Research
2019-2025
Frederick National Laboratory for Cancer Research
2022-2025
University of Kinshasa
2023-2024
Leidos Biomedical Research Inc. (United States)
2021-2022
Leidos (United States)
2021-2022
University Hospital of Lausanne
2019-2022
Hôpital Orthopédique de la Suisse Romande
2013-2020
National Institute of Allergy and Infectious Diseases
2015
National Institutes of Health
2015
Institut de Recherche Vaccinale
2015
Although several experimental therapeutics for Ebola virus disease (EVD) have been developed, the safety and efficacy of most promising therapies need to be assessed in context a randomized, controlled trial.
The worst Ebola virus disease (EVD) outbreak in history has resulted more than 28,000 cases and 11,000 deaths. We present the final results of two phase 1 trials an attenuated, replication-competent, recombinant vesicular stomatitis (rVSV)-based vaccine candidate designed to prevent EVD.
The West African outbreak of Ebola virus disease that peaked in 2014 has caused more than 11,000 deaths. development an effective vaccine is a priority for control future outbreak.
The 2014 west African Zaire Ebola virus epidemic prompted worldwide partners to accelerate clinical development of replication-defective chimpanzee adenovirus 3 vector vaccine expressing glycoprotein (ChAd3-EBO-Z). We aimed investigate the safety, tolerability, and immunogenicity ChAd3-EBO-Z in Malian US adults, assess effect boosting Malians with modified vaccinia Ankara other filovirus antigens (MVA-BN-Filo).
Tecovirimat is available for the treatment of mpox (formerly known as monkeypox) in Europe and United States, on basis findings from efficacy studies animals safety evaluations healthy humans. Evidence randomized, controlled trials patients with lacking. We conducted a double-blind, placebo-controlled trial tecovirimat Democratic Republic Congo (DRC). Patients at least one skin lesion positive polymerase-chain-reaction results clade I MPXV were assigned 1:1 ratio to receive or placebo. All...
To evaluate Enhanced recovery after surgery (ERAS®) protocol on oncological outcomes for patients treated with radical cystectomy (RC) urothelial carcinoma of the bladder (UCB).A prospectively maintained single-institutional database comprising 160 consecutive UCB who underwent open RC from 2012 to 2020 was analyzed. Patients receiving chemotherapy and those a urinary diversion other than ileal conduit were excluded. divided into two groups according perioperative management (ERAS®...
In response to the COVID-19 pandemic, vaccines have been developed, and World Health Oraganization (WHO) has granted emergency use listing multiple vaccines. Studies of vaccine immunogenicity data from implementing by national immunization programs in single studies spanning countries continents are limited but critically needed answer public health questions on vaccines, such as comparing immune responses different among populations.
During the 2018-20 Ebola virus disease outbreak in Democratic Republic of Congo, thousands patients received unprecedented vaccination, monoclonal antibody (mAb) therapy, or both, leading to a large number survivors. We aimed report clinical, virological, viral genomic, and immunological features two previously vaccinated mAb-treated survivors Congo who developed second episodes months after initial discharge, ultimately complicated by fatal meningoencephalitis associated with persistence.
Objectives: Enhanced Recovery after Surgery (ERAS) reduces morbidity and length of stay in colorectal surgery. The present study assesses the impact an ERAS protocol applied to nephrectomy patients, which extend minimal invasive surgery (MIS) influences outcomes. Methods: From January 2011 December 2014, consecutive patients undergoing radical or partial nephro-ureterectomy were included. Since October 2012, all prospectively enrolled care pathway incorporating 22 multimodal elements. These...